Top executives at the three largest pharmacy benefit managers largely stuck to the script despite bipartisan skepticism and the growing frustration of the House Oversight and Accountability Committee with their testimony during a third hearing on industry reforms.
PBM Execs Stay On Message Amid Growing US Congressional Frustration At Hearing
The House Oversight Committee held its third hearing on pharmacy benefit manager reforms in 14 months, but could not elicit an admission from executives that they are responsible for increasing drug prices.
More from Market Access
More from Pink Sheet
• By
Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.
• By
Coverage data from the two programs suggest Medicare beneficiaries may be more disappointed than Medicaid enrollees by the Trump Administration’s decision not to mandate the programs cover obesity drugs.
• By
The new telework policy returns to the pre-COVID-19 pandemic standard, but still requires reviewers to be at White Oak for sponsor meetings and divisions to have an in-office presence every day.